Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
MNKD
MNKD
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
MNKD News
MannKind Launches Pediatric Diabetes Clinical Study for Afrezza
6d ago
Newsfilter
Longevity Infrastructure Market Undergoes Structural Reset
Jan 29 2026
PRnewswire
Global Capital Shifts to Longevity Infrastructure Valued at $27 Trillion
Jan 29 2026
Newsfilter
Avant Technologies Leads Transformation in Healthcare Market
Jan 26 2026
PRnewswire
Avant Technologies Leads Medical Innovation with Next-Gen Treatments
Jan 26 2026
Newsfilter
MannKind Receives FDA Approval for Afrezza Label Update
Jan 26 2026
NASDAQ.COM
MannKind's Afrezza Receives FDA Label Update Approval
Jan 26 2026
stocktwits
Avant Technologies Unveils Cell Encapsulation Tech to Address 589 Million Diabetes Patients' Needs
Jan 23 2026
Globenewswire
Avant Technologies Unveils Cell Encapsulation Tech, Tapping into Diabetes Market Potential
Jan 23 2026
Newsfilter
MannKind Acquires scPharmaceuticals, Expects Over $100M Net Revenue in 2026
Jan 08 2026
Globenewswire
MannKind CEO Castagna Sells 65,804 Shares for Approximately $395,482
Dec 25 2025
Fool
MannKind CEO Castagna Sells 65,804 Shares for ~$395,482
Dec 25 2025
NASDAQ.COM
Nitorum Capital Exits Lantheus Holdings Stake with $28.2 Million Transaction
Dec 24 2025
Fool
MannKind Receives FDA Approval for FUROSCIX in Pediatric Patients Over 43kg
Dec 23 2025
Globenewswire
MannKind's FUROSCIX ReadyFlow Autoinjector Submitted for FDA Review; PDUFA Date Scheduled for July
Dec 02 2025
NASDAQ.COM
MannKind Seeks FDA Approval for ReadyFlow Autoinjector to Deliver Diuretic in Under 10 Seconds
Dec 01 2025
Globenewswire
Show More News
